Comparative Pharmacology
Head-to-head clinical analysis: LEVITRA versus SILDAFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVITRA versus SILDAFLO.
LEVITRA vs SILDAFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and blood flow into the corpus cavernosum, thereby facilitating erection.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (cGMP) levels in vascular smooth muscle.
10 mg orally once daily as needed, 1 hour before sexual activity; range 5-20 mg based on efficacy and tolerability; maximum dosing frequency once daily.
50 mg orally once daily, approximately 1 hour before sexual activity; or 100 mg orally once daily maximum dose. Alternatively, 25 mg orally once daily for elderly or patients with renal impairment. Dose may be increased to 100 mg or decreased to 25 mg based on efficacy and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy subjects; prolonged in elderly (>65 years) and in hepatic impairment.
Terminal elimination half-life is approximately 4-5 hours in healthy adults; may be prolonged in elderly patients and those with hepatic impairment.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (approximately 90-95% of dose) and urine (approximately 2-6% of dose as unchanged drug).
Primarily hepatic metabolism (>80%) with metabolites excreted in feces (approximately 70-80% of dose) and urine (approximately 20-30% as metabolites); less than 1% excreted unchanged in urine.
Category C
Category C
Phosphodiesterase-5 Inhibitor
Phosphodiesterase-5 Inhibitor